Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens

Cancer Research

Volumn 70, Issue 19, 2010, Pages 7442-7454

  Geng, Degui ^a,b   Zheng, Liqin ^c   Srivastava, Ratika ^a,b   Velasco Gonzalez, Cruz ^d   Riker, Adam ^e   Markovic, Svetomir N ^f   Davila, Eduardo ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b Department of Otorhinolaryngology ^*  (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Department of Pathology   (United States)

^e JO EF STEFAN INSTITUTE   (Slovenia)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID DIFFERENTIATION FACTOR 88; THYMOMA; TOLL-LIKE RECEPTOR 2;

EID: 77957361069     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0247     Document Type: Article

References (37)

1. + T cells in patients with melanoma. J Immunol 2005;175:6169-76.
2. Coulie PG, Somville M, Lehmann F, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992;50:289-97.
3. Ford ML, Koehn BH, Wagener ME, et al. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 2007;204:299-309.
4. Boon T, Cerottini JC, Van den EB, van der BP, Van PA. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
5. de Visser KE, Cordaro TA, Kioussis D, Haanen JB, Schumacher TN, Kruisbeek AM. Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur J Immunol 2000;30:1458-68.
6. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 1998;160:643-51.
7. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95.
8. Bendigs S, Salzer U, Lipford GB, Wagner H, Heeg K. CpG- oligodeoxynucleotides costimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol 1999;29:1209-18.
9. + T cells. J Immunol 2005;175:1551-7.
10. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 2004;101:3029-34.
11. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez- Perez L, Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J 2008;22:3628-37.
12. Cottalorda A, Verschelde C, Marcais A, et al. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol 2006;36:1684-93.
13. + T cell survival. J Immunol 2004;172:6065-73.
14. Zheng L, Asprodites N, Keene AH, Rodriguez P, Brown KD, Davila E. TLR9 engagement on CD4 T lymphocytes represses {γ}-radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood 2008;111:2704-13.
15. Buwitt-Beckmann U, Heine H, Wiesmuller KH, et al. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 2006;281:9049-57.
16. Cottalorda A, Mercier BC, Mbitikon-Kobo FM, et al. TLR2 engagement on memory CD8(+) T cells improves their cytokine-mediated proliferation and IFN-γ secretion in the absence of Ag. Eur J Immunol 2009;39:2673-81.
17. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998; 188:277-86.
18. + T cell expansion with variable dependence on type I IFN. J Exp Med 2004;199:775-84.
19. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/ protein immunization results in enhanced CTL responses with antitumor activity. J Immunol 2000;165:539-47.
20. Ingalls RR, Lien E, Golenbock DT. Differential roles of TLR2 and TLR4 in the host response to Gram-negative bacteria: lessons from a lipopolysaccharide- deficient mutant of Neisseria meningitidis. J Endotoxin Res 2000;6:411-5.
21. + T cells. J Exp Med 2005;202:907-12.
22. Hellstrom KE, Hellstrom I. Evidence that tumor antigens enhance tumor growth in vivo by interacting with a radiosensitive (suppressor?) cell population. Proc Natl Acad Sci U S A 1978;75:436-40.
23. Hellstrom KE, Hellstrom I, Kant JA, Tamerius JD. Regression and inhibition of sarcoma growth by interference with a radiosensitive T cell population. J Exp Med 1978;148:799-804. (Pubitemid 9006461)
24. North RJ. Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells. J Exp Med 1986;164:1652-66.
25. + T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 2009;106:17469-74.
26. + T cells via TLR4 signaling. J Clin Invest 2007;117:2197-204.
27. van dH I, Wilbrink B, Tchetverikov I, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000;43:593-8.
28. Sobek V, Birkner N, Falk I, et al. Direct Toll-like receptor 2 mediated costimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease. Arthritis Res Ther 2004;6:R433-46.
29. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277:15028-34.
30. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24.
31. Zanin-Zhorov A, Nussbaum G, Franitza S, Cohen IR, Lider O. T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. FASEB J 2003;17:1567-9.
32. + T cell population in LCMV-infected mice. J Gen Virol 2009;90:423-31.
33. Rahman AH, Cui W, LaRosa DF, et al. MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection. J Immunol 2008;181:3804-10.
34. Zhao Y, De TC, Flynn R, Ware CF, Croft M, Salek-Ardakani S. The adaptor molecule MyD88 directly promotes CD8 T-cell responses to vaccinia virus. J Immunol 2009;182:6278-86.
35. + T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 2006;25:783-93.
36. Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 overexpression enhances tumor-specific T cell survival. Cancer Res 2005;65:2001-8.
37. Glimcher LH, Townsend MJ, Sullivan BM, Lord GM. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol 2004;4:900-11.